(Bladder Cancer) Immune Clinical Trial Enrollment

A clinical trial is evaluating the feasibility of a new preoperative immunotherapy approach for bladder cancer patients: combining the PD-1 inhibitor Opdivo (nivolumab) with the CTLA-4 inhibitor Yervoy (ipilimumab). Cancer treatment has evolved rapidly in recent years. Beyond traditional surgery, radiation, and chemotherapy, targeted therapies have flourished over the past two decades. With advances in medical research, scientists have uncovered the complex interactions between the human immune system and tumor cells, driving the rise of immunotherapy as another important milestone in cancer treatment.

The following eligibility criteria apply for inquiries about this clinical trial.

The trial procedure is outlined below.

Immune-related adverse event (irAE) references are also included.

About the Institution: Tung's Taichung MetroHarbour Hospital (童綜合醫院), a medical corporation located in central Taiwan, has approximately 1,200 beds. Established in Shalu, Taichung City in 1971, the hospital has provided over 47 years of distinguished medical services. Committed to continuous improvement, the hospital has continually invested in the latest medical technologies and equipment to provide patients with the highest quality of treatment and care.

Medical Supporter, affiliated with Shingihou Co., Ltd. in Japan, assists clients with clinical trial consultations in Taiwan and Japan. For further information about this bladder cancer clinical trial, please contact us through our official channels.

Official website: https://www.medicalsupporter.org

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7